Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy Sander Kelderman, Ton N. Schumacher, Pia Kvistborg  Cancer Cell  Volume 28, Issue 1, Pages 11-13 (July 2015) DOI: 10.1016/j.ccell.2015.06.012 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Potential Mechanisms of Action of Anti-PD-1 Therapy in Mismatched Repair-Deficient Tumors (A) MMR deficiency results in a more diverse neo-antigen repertoire, increasing the chances of a tumor-specific T cell response. (B) MMR deficiency is associated with the activation of signaling pathways, which leads to a more inflammatory tumor micro-environment. (C) MMR deficiency leads to cellular stress, which, for instance, promotes T or NK cell accumulation or tumor recognition. Cancer Cell 2015 28, 11-13DOI: (10.1016/j.ccell.2015.06.012) Copyright © 2015 Elsevier Inc. Terms and Conditions